1. Lipoteichoic acid from Bifidobacterium animalis subsp. lactis BPL1: a novel postbiotic that reduces fat deposition via IGF-1 pathway
- Author
-
Silvia Llopis, Marta Tortajada, Empar Chenoll, Marta Barrena, Patricia Martorell, Daniel Ramón, Beatriz Alvarez, Ferran Balaguer, María Enrique, and Verónica Navarro
- Subjects
Lipopolysaccharides ,Bioengineering ,Context (language use) ,Pharmacology ,Applied Microbiology and Biotechnology ,Biochemistry ,law.invention ,03 medical and health sciences ,Probiotic ,Bifidobacterium animalis ,law ,Diabetes mellitus ,medicine ,Animals ,Obesity ,Insulin-Like Growth Factor I ,Caenorhabditis elegans ,030304 developmental biology ,0303 health sciences ,Adipogenesis ,biology ,030306 microbiology ,Chemistry ,Probiotics ,medicine.disease ,biology.organism_classification ,Teichoic Acids ,Lipoteichoic acid ,Metabolic syndrome ,Function (biology) ,Biotechnology - Abstract
Obesity and its related metabolic disorders, such as diabetes and cardiovascular disease, are major risk factors for morbidity and mortality in the world population. In this context, supplementation with the probiotic strain Bifidobacterium animalis subsp. lactis BPL1 (CECT8145) has been shown to ameliorate obesity biomarkers. Analyzing the basis of this observation and using the pre-clinical model Caenorhabditis elegans, we have found that lipoteichoic acid (LTA) of BPL1 is responsible for its fat-reducing properties and that this attribute is preserved under hyperglycaemic conditions. This fat-reducing capacity of both BPL1 and LTA-BPL1 is abolished under glucose restriction, as a result of changes in LTA chemical composition. Moreover, we have demonstrated that LTA exerts this function through the IGF-1 pathway, as does BPL1 strain. These results open the possibility of using LTA as a novel postbiotic, whose beneficial properties can be applied therapeutically and/or preventively in metabolic syndrome and diabetes-related disorders.
- Published
- 2021